PBSV Pharma-Bio Serv, Inc.
Services-Management Consulting Services · OTC · SEC CIK 1304161 · Fiscal year ends 10/31
Financial factors as of 2026-07-31 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.3%
TTM net income YoY398.5%
TTM EPS YoY115.1%
Revenue 3-yr CAGR-19.3%
Net income 3-yr CAGR-45.2%
Margins
Gross margin32.3%
Operating margin-1.6%
Net margin2.7%
FCF margin-4.4%
EBITDA margin-1.0%
Returns
ROE2.2%
ROA2.0%
ROIC (approx.)-1.7%
Asset turnover0.76x
Leverage & solvency
Liabilities / assets8.7%
Debt / equity0.00x
Current ratio11.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-1.65x
Accruals ratio5.3%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-07-31 | 2026Q22026-04-30 | 2026Q12026-01-31 | 2025Q4*2025-10-31 | 2025Q32025-07-31 | 2025Q22025-04-30 | 2025Q12025-01-31 | 2024Q4*2024-10-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.34M | $2.70M | $2.29M | $2.15M | $1.96M | $2.42M | $2.47M | $2.33M |
| Cost of revenue | $1.64M | $1.80M | $1.57M | $1.40M | $1.39M | $1.60M | $1.70M | $1.61M |
| Gross profit | $691,734 | $902,041 | $722,374 | $748,935 | $574,262 | $818,726 | $768,109 | $726,570 |
| SG&A expense | $763,546 | $757,365 | $816,909 | $882,207 | $888,139 | $917,048 | $860,300 | $880,700 |
| Operating income | -$71,812 | $144,676 | -$94,535 | -$133,272 | -$313,877 | -$98,322 | -$92,191 | -$154,130 |
| Pretax income | -$11,098 | $239,353 | $36,490 | $4,254 | -$209,029 | $100,864 | $9,651 | -$14,849 |
| Income tax | $3,121 | $6,367 | $3,630 | $4,356 | -$4,779 | $5,511 | $1,115 | -$30,960 |
| Net income | -$14,219 | $232,986 | $32,860 | -$102 | -$204,250 | $95,353 | $8,536 | $16,111 |
| EBITDA | -$58,127 | $158,316 | -$79,739 | -$117,455 | -$298,133 | -$79,456 | -$82,752 | -$148,202 |
| EPS (diluted) | -0.00 | 0.01 | 0.00 | — | -0.01 | 0.00 | 0.00 | — |
| Weighted avg. shares (diluted) | 22.91M | 22.91M | 22.91M | — | 22.94M | 22.94M | 22.96M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.52M | $1.79M | $5.76M | $3.38M | $3.96M | $2.09M | $7.31M | $6.77M |
| Short-term investments | $7.06M | $6.68M | $4.80M | $7.48M | $6.77M | $8.31M | $5.13M | $5.98M |
| Receivables | $2.42M | $2.72M | $2.65M | $2.36M | $2.02M | $2.68M | $2.68M | $2.51M |
| Current assets | $11.24M | $11.29M | $13.32M | $13.39M | $13.16M | $13.42M | $15.53M | $15.70M |
| PP&E, net | $80,060 | $92,355 | $103,674 | $116,059 | $131,526 | $145,234 | $159,842 | $169,281 |
| Total assets | $11.44M | $11.50M | $13.55M | $13.65M | $13.59M | $13.90M | $16.08M | $16.29M |
| Current liabilities | $994,740 | $1.05M | $3.31M | $1.74M | $1.66M | $1.78M | $3.42M | $1.89M |
| Total liabilities | $994,740 | $1.05M | $3.31M | $1.74M | $1.66M | $1.78M | $4.08M | $2.58M |
| Shareholders' equity | $10.44M | $10.45M | $10.24M | $11.91M | $11.93M | $12.12M | $12.00M | $13.72M |
| Shares outstanding | 22.90M | 22.90M | 22.90M | 22.91M | 22.92M | 22.93M | 22.96M | 22.96M |
| Cash flow statement | ||||||||
| Operating cash flow | $60,892 | -$365,311 | -$390,139 | $279,666 | $236,524 | -$301,590 | -$429,486 | $78,425 |
| Capital expenditure | $1,390 | $2,321 | $2,411 | $350 | $2,036 | $4,258 | $0 | $157,015 |
| Free cash flow | $59,502 | -$367,632 | -$392,550 | $279,316 | $234,488 | -$305,848 | -$429,486 | -$78,590 |
| Investing cash flow | -$326,303 | -$1.89M | $2.77M | -$856,665 | $1.63M | -$3.23M | $988,338 | $171,532 |
| Financing cash flow | $0 | -$1.72M | -$1,681 | -$9,202 | -$5,004 | -$1.74M | $0 | $0 |
| Depreciation & amortization | $13,685 | $13,640 | $14,796 | $15,817 | $15,744 | $18,866 | $9,439 | $5,928 |
| Stock-based compensation | $8,620 | $8,619 | $8,619 | $4,399 | $9,999 | $10,000 | $10,681 | $3,146 |
| Dividends paid | $0 | $1.72M | — | $0 | $0 | $1.72M | — | $0 |
| Share buybacks | $0 | $709 | $1,681 | $9,202 | $5,004 | $17,237 | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.